Topic: Biotech

Parkinson’s disease patients lack sufficient amounts of a neurotransmitter that plays a key role in […]

Testing giant Quest Diagnostics is diving into the market for blood tests that aid in […]

Bristol Myers Squibb and Merck KGaA are diving deeper into the protein degradation pool, with […]

Norovirus sickens hundreds of millions of people around the world each year, sparking infection that […]

There’s no safe way to get a close-up view of the human heart as it […]

Gandeeva Therapeutics, founded in 2021, is developing precision imaging solutions with the integration of cryo-electron microscopy […]

The first cell therapies for cancer employ T cells turned into targeted tumor fighters. Nkarta […]

Arrowhead and Vivo Capital are forming a new company called Visirna Therapeutics to take four […]

Chalk up another setback to oral selective estrogen receptor degraders (SERDs). In the wake of […]

Scientists at Penn State developed a method to print a ‘bone’ construct during a surgical […]

Biosynthetic cellulose offers potential for applications such as wound dressings, implantable materials, and drug-delivery systems. […]

Tessera Therapeutics, founded and created by life sciences VC staple Flagship Pioneering, is building a […]

AbbVie is bowing out of the alpha-synuclein race. Having taken a drug candidate to the […]

Ankyra Therapeutics is bringing on outside expertise to support its bid to unlock the power of cytokines. […]

Integer (NYSE:ITGR) announced today that it acquired Connemara Biomedical and its subsidiaries Aran Biomedical and Proxy Biomedical (collectively […]

Bausch Health’s (NYSE:BHC) Bausch + Lomb and Clearside Biomedical (NSDQ:CLSD) today launched their Xipere product […]

Altos Labs just redefined big in biotech. Where to start? The $3 billion in investor support? The […]

Thermo Fisher Scientific (NYSE:TMO) announced today that it completed its acquisition of PeproTech for approximately $1.85 […]

Amazon (NASDAQ: AMZN) wants to hire key employees to expand its medical diagnostics operations on […]

Biotechs targeting the “don’t eat me” signal cancer cells use to avoid the immune system […]

Illumina (NSDQ:ILMN) announced that it completed its long-awaited and much-scrutinized acquisition of cancer detection company Grail. In […]

Vigil Neuroscience is barreling forward with a strategy that will see it hop along steppingstones […]

Waltham, MA-based Thermo Fisher Scientific was granted emergency use authorization for the TaqPath COVID-19 Fast PCR Combo Kit 2.0 and the TaqPath COVID-19 RNase P Combo Kit 2.0 assays.

CAR-T treatments like Novartis’ Kymriah have proven effective in some B-cell-driven cancers, with one notable […]

PureTech Health has pieced together a wholly owned pipeline in recent years, picking up a […]

AbbVie has advanced its collaboration with Mission Therapeutics after getting a look at data from preclinical models of […]

PepGen has raised $112.5 million to take a treatment for Duchenne muscular dystrophy (DMD) into the clinic […]

Sanofi has struck a deal to buy its mRNA partner Translate Bio in a $3.2 billion deal. […]

The funds will be used to accelerate HMNC’s pipeline development towards market maturity.

Just two months after getting a swift approval for its closely watched KRAS lung cancer […]

Seven years ago, AbbVie penned an early-stage deal with Google/Alphabet’s life sciences division Calico: The […]

Artios Pharma has raised $153 million to take its DNA damage response (DDR) pipeline deeper […]

Glaucoma can cause blindness and has no cure, as current therapies only slow vision loss […]

Hemab has raised $55 million to advance a pipeline of bispecific and monoclonal antibodies to […]

Panakès has raised a €150 million ($177 million) fund that will extend its focus beyond medtech […]

GlaxoSmithKline is planning to sell more than one-third of its 92-acre R&D site in Stevenage, U.K. The […]

Scientists from Ohio State University have developed a novel method for delivering gene therapy to […]

PAQ Therapeutics hopes to break into the emerging field of autophagy, which is essentially the […]

Eli Lilly is looking to shore up its future diabetes franchise by putting $1 billion on the table to buy out next-gen biotech Protomer.